Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 50mg | $28.99$15.78 | $0.32/mg | Out of stock | Jul 7 |
| vial | 100mg | $49.99 | $0.50/mg | Out of stock | Jul 7 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| GK-31126328 | — | 99.6% | Analytical Formulations, Inc. | Heavy metals | Unverified | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. GHK-Cu is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Alpha Peptides sell GHK-Cu?
Yes — Alpha Peptides currently lists GHK-Cu in 2 variants starting at $15.78 ($0.32/mg).
Is Alpha Peptides's GHK-Cu third-party tested?
Yes — Disclosed Labs has indexed 1 Certificate of Analysis for Alpha Peptides's GHK-Cu, with the most recent showing 99.6% purity. Alpha Peptides holds an overall trust grade of C (71/100) across all 12 COAs on file.
What is Alpha Peptides's trust grade for GHK-Cu?
Alpha Peptides has an overall Disclosed Labs trust grade of C (71/100), computed from 12 COAs across all peptides. The most recent GHK-Cu COA was issued by Analytical Formulations, Inc..
Where is the cheapest GHK-Cu?
As of the latest data, Sunrise Bioresearch offers GHK-Cu at $0.09/mg — compare with Alpha Peptides's listing at $0.32/mg. See the full GHK-Cu price comparison.
Is GHK-Cu legal to buy?
GHK-Cu is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
Disclosed Labs